Search
Dinutuximab
go.drugbank.com/drugs/DB09077ApprovedInvestigationalrestricted expression on normal tissues. … Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly
Acipimox
go.drugbank.com/drugs/DB09055ApprovedInvestigationalAcipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL. … It is used in low doses and may have less marked adverse effects, although it is unclear whether the recommended dose is as effective as are standard doses of nicotinic acid.
Mifepristone
go.drugbank.com/drugs/DB00834ApprovedInvestigationalCurrently under investigation for use in psychotic depression (phase 3 trials). … As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome.
Iodoform
go.drugbank.com/drugs/DB13813ApprovedInvestigationalVet approvedWithdrawnIodoform is soluble in fatty acids and decomposes releasing iodine in nascent state (96,7% of iodine) when in contact with secretions or endodontic infections [A32893]. … Iodoform has also been found in dental paste and root canal filling materials in combination with other intracanal medications due to its radiopacity [A32893].
2-deoxyglucose
go.drugbank.com/drugs/DB08831InvestigationalAs an experimental drug, 2-deoxyglucose was demonstrated to work as an anticonvulsant in temporal lobe epilepsy. … Therapeutically, 2-deoxyglucose is an investigational drug that is being studied as an anticancer and antiviral agent.
Plasminogen
go.drugbank.com/drugs/DB16701ApprovedInvestigational[L34615] It is the first and only FDA-approved treatment for this condition, which causes wood-like lesions to form on the mucous membranes of patients, providing an unmet medical need for patients with … [L34635] In June 2021, the FDA approved a plasma-derived plasminogen (Ryplazim, human plasminogen-tvmh)[L34620] for the treatment of type 1 plasminogen deficiency (hypoplasminogenemia).
REN-850
go.drugbank.com/drugs/DB05912ExperimentalREN-850 is an oral drug for multiple sclerosis which is in Phase I of clinical trials.
Chymotrypsin
go.drugbank.com/drugs/DB09375ApprovedInvestigationalVet approvedWithdrawnIt is a serine protease synthesized in the pancreas and is a vital component in the pancreatic juice. … Chymotrypsin (EC 3.4.21.1) is a digestive enzyme that promotes proteolysis, or the breakdown of proteins and polypeptides.
Denileukin diftitox
go.drugbank.com/drugs/DB00004ApprovedInvestigationalon August 8, 2024. … approved to treat a human disease in the US.
Synonyms: N-MET-187-HIS-388-ALA-1-388-TOXIN (CORYNEBACTERIUM DIPHTHERIAE C7) WITH 1-133-INTERLEUKIN 2, N-L-METHIONYL-387-L-HISTIDINE-388-L-ALANINE-1-388-TOXIN (CORYNEBACTERIUM DIPHTHERIAE STRAIN C7) (388->2') PROTEIN WITH 2-133-INTERLEUKIN 2 (HUMAN CLONE PTIL2-21A)Medroxyprogesterone acetate
go.drugbank.com/drugs/DB00603ApprovedInvestigationalmanage pain in endometriosis, prevent pregnancy, and is also used in palliative care for endometrial and renal carcinoma. … [L8657,L8660,L8663,L8666,L8669] Medroxyprogesterone acetate was granted FDA approval on 18 June 1959.[L8657]
Synonyms: (6α)-17-(Acetyloxy)-6-methylpreg-4-ene-3,20-dioneProducts: Gen-medroxy Tablet 5mg, Gen-medroxy Tablet 10mg